NTRK2 and major depressive disorder: A recent gene-based genome-wide association study in Taiwan showed the predictive role of BDNF–TrkB signaling, glutamatergic signaling, and GABAergic signaling in the antidepressant actions of (R,S)-ketamine in patients with treatment-resistant MDD [122].